Ionis Pharmaceuticals, Inc. (IONS) — Financial statements
Income statement, balance sheet, and cash flow for Ionis Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 944↑33.9% | 705↓10.5% | 788↑34.1% | 587↓27.5% | 810 | |
| Cost of Revenue | 16↑42.7% | 11↑22.8% | 9↓35.3% | 14↑30.2% | 11 | |
| Gross Profit | 928↑33.7% | 694↓10.9% | 779↑35.8% | 573↓28.3% | 800 | |
| Operating Expenses | ||||||
| R&D Expenses | 916↑1.6% | 902↑0.2% | 900↑8.0% | 833↑29.5% | 643 | |
| General & Administrative Expenses | 0.00↓100.0% | 268↑15.0% | 233↑54.8% | 150↓12.1% | 171 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↑100.0% | -0.01 | 0.00 | |
| SG&A Expenses | 394↑47.3% | 268↑15.0% | 233↑54.8% | 150↓12.1% | 171 | |
| Other Expenses | 0.00↑100.0% | -0.03↓236.8% | 0.02↓87.1% | 0.15↓99.1% | 16 | |
| Operating Expenses | 1,310↑12.1% | 1,169↑3.2% | 1,132↑15.1% | 983↑18.5% | 830 | |
| Total Costs & Expenses | 1,326↑12.4% | 1,180↑3.4% | 1,141↑14.4% | 998↑18.7% | 841 | |
| Operating Results | ||||||
| Operating Income | -382↑19.6% | -475↓34.3% | -354↑13.8% | -410↓1258.9% | -30 | |
| Depreciation & Amortization | 20↓7.9% | 22↓2.3% | 22↑1.8% | 22↑13.0% | 20 | |
| EBITDA | -287↑18.9% | -354↓50.0% | -236↓3.6% | -228↓4290.1% | -5 | |
| EBIT | -307↑18.3% | -376↓45.4% | -258↓3.4% | -250↓909.6% | -25 | |
| Interest & Other Income | ||||||
| Net Interest Income | -73↓540.5% | 17↑118.5% | 8↓55.9% | 17↑2376.1% | 0.70 | |
| Interest Income | 0.00↓100.0% | 107↑20.2% | 89↑251.5% | 25↑152.2% | 10 | |
| Interest Expense | 73↓19.3% | 90↑11.0% | 81↑902.9% | 8↓13.1% | 9 | |
| Non-Operating Income | -75↑24.5% | -99↓4.2% | -95↑40.5% | -160↓2848.3% | -5 | |
| Other Income / Expenses | 2↓86.7% | 15↓24.0% | 20↓87.0% | 152↑14563.4% | 1 | |
| Income Before Tax | -380↑17.4% | -460↓37.8% | -334↓29.5% | -258↓785.1% | -29 | |
| Income Tax Expense | 1↑116.2% | -6↓119.1% | 32↑175.4% | 12↑2230.1% | -0.55 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -381↑16.1% | -454↓23.9% | -366↓35.8% | -270↓843.2% | -29 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -381↑16.1% | -454↓23.9% | -366↓35.8% | -270↓843.2% | -29 | |
| Bottom-Line Net Income | -381↑16.1% | -454↓23.9% | -366↓35.8% | -270↓843.2% | -29 | |
| EPS (Basic) | -2.38↑21.7% | -3.04↓18.8% | -2.56↓34.7% | -1.90↓850.0% | -0.20 | |
| EPS (Diluted) | -2.38↑21.7% | -3.04↓18.8% | -2.56↓34.7% | -1.90↓850.0% | -0.20 | |
| Weighted Average Shares | 160↑7.0% | 150↑4.6% | 143↑0.8% | 142↑0.6% | 141 | |
| Weighted Average Diluted Shares | 160↑7.0% | 150↑4.4% | 143↑0.9% | 142↑0.6% | 141 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.